The kids have their fall break so I am working from home but wanted to provide at least a couple of thoughts as there has been some news. It will be very interesting to see if the sector keeps the positive momentum of yesterday after what seems to be significantly negative clinical news. One might […]
October 4th Biotech Update
The sector is at an odd sort of place. It seemed to catch a break and had a reversal off of some support late last week and today we are back to the selling. It does not help that the broader market is not doing well either but at some point the sector has to […]
October 1st Biotech Update
The sector cannot catch a break as we get great clinical news this morning and it will likely end up hurting the sector more than helping. The question in my mind now is whether the support for the sector is $122 or $118 ranges as one cannot ignore the selling in response to positive news. […]
September 30th Biotech Update
What seemed like long rumored has come to pass with a decently sized deal in the sector. The reaction yesterday was quite negative and I think expectations on price got too high. I firmly believe that if this deal was announced last Monday (before the runup in XLRN started) at this exact same price the […]
April 5th Biotech Update
While it is possible that this week is decision week for the sector, I am not convinced that it has to be. There is room above and below for it to tread water and not signal its next big move. I see the $150 and $125 levels as the key ones to watch and the […]
November 15 Biotech Update
Today is an important day for the sector. We are at very long term support (the 200 week MA) that has rarely been breached (occasionally but never in a sustained manner). At levels that should provide some support we get some partnership news that is positive for SMID (it seems like partnerships are the new […]
Upcoming earnings and conferences this week
With the first quarter behind us, we look to updates across the biotech industry on new product launches and guidance for the year. We are also coming upon the summer medical conference series. Additionally, we briefly discuss 2 upcoming FDA approvals. Upcoming earnings releases and updates Monday, April 22nd After-Hours: ILMN Tuesday, April 23rd Pre-Market: […]
Biotech and Pharma earnings preview
Starting after-hours on Tuesday, we’ll see a lot of biotech and pharmaceuticals earnings, guidance, and outlook on their current programs. With the market cooling off, companies will be under pressure to meet investor expectations. Next week a number of sector leaders will kick things off. We’ve listed the updates in chronological order. Amgen (Nasdaq: AMGN) […]
An October full of data and decisions
With October underway, we felt the need to highlight some of the most important upcoming data readouts and regulatory decisions. This month is particularly busy on the regulatory side of things with 5 PDUFAs, 4 Advisory Committees, 6 FDA actions, and multiple potential European Medicines Agency(EMA) decisions. The events are listed in chronological order. Eli […]
